Open-innovation projects turn old R&D wisdom 'on its head'

The Guardian today highlights a number of initiatives underway that have been bringing biotechs, pharma companies, academic researchers, and even the general public into new "open innovation" therapeutic projects.

"Generally, drug development is expensive, takes a long time and most things don't work," Don Joseph, CEO of NGO BIO Ventures for Global Health, tells The Guardian. "The challenge is to create projects that are simple and allow a streamlined process for organizations to participate. (Open innovation partnerships could) significantly reduce trial and error, and lead neglected disease researchers to that 'Eureka moment' more quickly and effectively." 

"The prevailing logic was … if you want something done, do it yourself," adds Henry Chesbrough, the open innovation chief at the University of California. "This new logic of open innovation turns that completely on its head."

Initiatives now underway include The Re:search project, a joint effort by BIO Ventures and the World Intellectual Property Organization, an online crowdsourcing effort by Nature and InnoCentive, the Global Alliance for TB Drug Development, and the GAVI Alliance on new vaccines.

"The perceived barrier of intellectual property as a brake on collaboration in drug and vaccine development is, in our view, exaggerated," says Joseph.

- here's the article from The Guardian

Like what you're reading?

Click here to get more news like this delivered to your inbox every day>>